Table 3.
Characteristics of RCTs in an Exploratory Analysis
| Study | Design | No. | Patient | Intervention | Comparison | Median Follow-Up, mo |
|---|---|---|---|---|---|---|
| Reck et al., 201953 (IMpower150) |
Phase 3 (exploratory) | 124 | Non-SCC NSCLC harboring EGFR mutation (19del or L858R), stage IV, 18 y or older, ECOG PS 0–1, disease progression or intolerance to treatment with at least one TKI | ABCPa | BCPb | 19.6 |
| West et al., 201954 (IMpower130) |
Phase 3 (exploratory) | 44 | Non-SCC NSCLC harboring EGFR mutation or ALK translocation, stage IV, 18 y or older, ECOG PS 0–1, disease progression, or intolerance to treatment with at least one TKI | Atezolizumab plus CBDCA/nabPTX | CBDCA/nabPTX | 18.5 |
19del, exon 19 deletion; CBDCA, carboplatin; ECOG, Eastern Cooperative Oncology Group; nabPTX, nab-paclitaxel; PS, performance status; PTX, paclitaxel; RCT, randomized controlled trial; TKI, tyrosine kinase inhibitor.
a
ABCP, Atezolizumab plus CBDCA/PTX/bevacizumab.
b
BCP, CBDCA/PTX/bevacizumab.